Table 4.
Subgroup analyses of ORR and CBR.
| ORR, No (%) | p value | CBR, No (%) | p value | |
|---|---|---|---|---|
| Lung metastases | 0.787 | 0.007* | ||
| with (n=53) | 23 (43.40) | 16 (30.19) | ||
| without (n=78) | 32 (41.03) | 42 (53.85) | ||
| Bone metastases | 0.024* | 0.343 | ||
| with (n=58) | 18 (31.03) | 23 (39.66) | ||
| without (n=73) | 37 (50.68) | 35 (47.95) | ||
| No. of metastatic sites | 0.417 | 0.020* | ||
| ≤2 (n=78) | 35 (44.87) | 41 (52.56) | ||
| >2 (n=53) | 20 (37.74) | 17 (32.08) | ||
| Type of metastasis | 0.196 | 0.001* | ||
| non-visceral metastasis (n=26) | 8 (30.77) | 19 (73.08) | ||
| visceral metastasis (n=105) | 47 (44.76) | 39 (37.14) | ||
| Lines of pyrotinib | 0.008* | <0.001* | ||
| first-line (n=33) | 21 (63.64) | 27 (81.82) | ||
| second-line (n=47) | 19 (40.43) | 13 (27.66) | ||
| third-or-post-line (n=51) | 15 (29.41) | 18 (35.29) | ||
| Exposure to lapatinib | 0.019* | 0.599 | ||
| no prior exposure (n=113) | 52 (46.02) | 49 (43.36) | ||
| prior exposure (n=18) | 3 (16.67) | 9 (50.00) |
ORR: Objective response rate; CBR: Clinical Benefit Rate